Education
About Us
Working with TipRanks
Follow Us
Staar Surgical (STAA)
NASDAQ:STAA
STAA Stock Chart & Stats
$19.90
-$1.18(-4.94%)
At close: 4:00 PM EST
$19.90
-$1.18(-4.94%)
Day’s Range― - ―
52-Week Range$14.69 - $30.81
Previous CloseN/A
Volume326.32K
Average Volume (3M)1.57M
Market Cap
$989.86M
Enterprise Value$845.34M
Total Cash (Recent Filing)$192.66M
Total Debt (Recent Filing)$39.12M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Mar 03, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding49,741,955
10 Day Avg. Volume1,293,120
30 Day Avg. Volume1,566,820
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.99
Price to Sales (P/S)3.79
P/FCF Ratio-155.08
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.96
Enterprise Value/Ebitda-15.59
Forecast
1Y Price Target
$21.13Price Target Upside6.18% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.43
Revenue Forecast (FY)$309.89M
Bulls Say, Bears Say
Bulls Say
Acquisition DynamicsAn increased acquisition offer combined with reduced executive payouts could sway proxy advisor opinions and boost the probability of a shareholder-approved transaction that delivers premium value.
Board CompositionBroadwood Partners' appointment to the board and the addition of major shareholder representatives increases likelihood of a strategic refocus on profitability and disciplined growth initiatives.
Product ExecutionStrong execution of the EVO ICL program and positive technology assessments support potential for wider clinical adoption and improved commercial momentum.
Bears Say
Addressable Market SizeThe EVO ICL targets a relatively small group of high-myopia patients who often pay out of pocket, limiting the long-term addressable market and scalability of sales.
China Market ExposureHeavy reliance on Asian markets, especially China, leaves revenue visibility constrained as softer demand and rising local competition weigh on growth prospects.
Corporate Governance UncertaintyRejection of the proposed acquisition and a looming contested proxy fight signal prolonged leadership uncertainty that could distract management, lower employee engagement, and hamper execution.
Staar Surgical News
STAA FAQ
What was Staar Surgical’s price range in the past 12 months?
Staar Surgical lowest stock price was $14.69 and its highest was $30.81 in the past 12 months.
What is Staar Surgical’s market cap?
Staar Surgical’s market cap is $989.86M.
When is Staar Surgical’s upcoming earnings report date?
Staar Surgical’s upcoming earnings report date is Mar 03, 2026 which is today.
How were Staar Surgical’s earnings last quarter?
Staar Surgical released its earnings results on Nov 05, 2025. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.246 by $0.094.
Is Staar Surgical overvalued?
According to Wall Street analysts Staar Surgical’s price is currently Undervalued.
Does Staar Surgical pay dividends?
Staar Surgical does not currently pay dividends.
What is Staar Surgical’s EPS estimate?
Staar Surgical’s EPS estimate is 0.18.
How many shares outstanding does Staar Surgical have?
Staar Surgical has 49,741,955 shares outstanding.
What happened to Staar Surgical’s price movement after its last earnings report?
Staar Surgical reported an EPS of $0.34 in its last earnings report, beating expectations of $0.246. Following the earnings report the stock price went up 5.465%.
Which hedge fund is a major shareholder of Staar Surgical?
Currently, no hedge funds are holding shares in STAA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$21.13 (6.18% Upside)
$21.13 (6.18% Upside)
Hedge Fund Trend
Decreased
By 58.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.87%
12-Months-Change
Fundamentals
Return on Equity
-24.65%
Trailing 12-Months
Asset Growth
-15.11%
Trailing 12-Months
Company Description
Staar Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAA Stock 12 Month Forecast
Average Price Target
$21.13
▲(6.18% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---